Ion Beam (IBAB) | Financial Analysis & Statements
Ion Beam Applications S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
627.0M
Total Liabilities
508.0M
Shareholders Equity
119.0M
Debt to Equity
4.27
Cash Flow Metrics
Revenue & Profitability Trend
Ion Beam Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | 498.2M | 466.7M | 361.3M | 313.0M |
| Cost of Goods Sold | - | 332.2M | 332.2M | 234.5M | 205.3M |
| Gross Profit | - | 166.0M | 134.4M | 126.8M | 107.7M |
| Gross Margin % | 0.0% | 33.3% | 28.8% | 35.1% | 34.4% |
| Operating Expenses | |||||
| Research & Development | - | 58.0M | 47.9M | 41.8M | 34.0M |
| Selling, General & Administrative | - | 90.7M | 80.1M | 73.9M | 59.2M |
| Other Operating Expenses | - | 6.4M | 64.0K | 3.2M | - |
| Total Operating Expenses | 0 | 155.1M | 128.1M | 118.9M | 93.2M |
| Operating Income | - | 9.9M | 5.3M | 5.0M | 13.7M |
| Operating Margin % | 0.0% | 2.0% | 1.1% | 1.4% | 4.4% |
| Non-Operating Items | |||||
| Interest Income | - | 1.9M | 1.6M | 1.5M | 491.0K |
| Interest Expense | - | 2.2M | 2.0M | 2.1M | 2.5M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | - | 14.9M | -315.0K | -430.0K | 8.3M |
| Income Tax | - | 5.6M | 8.8M | -6.5M | 4.4M |
| Effective Tax Rate % | 0.0% | 37.9% | 0.0% | 0.0% | 53.0% |
| Net Income | - | 9.3M | -9.1M | 6.1M | 3.9M |
| Net Margin % | 0.0% | 1.9% | -2.0% | 1.7% | 1.2% |
| Key Metrics | |||||
| EBITDA | - | 24.2M | 17.2M | 18.8M | 25.9M |
| EPS (Basic) | €0.43 | €0.32 | €-0.31 | €0.21 | €0.13 |
| EPS (Diluted) | €0.43 | €0.31 | €-0.31 | €0.20 | €0.13 |
| Basic Shares Outstanding | 29323266 | 29253763 | 29181437 | 29143354 | 29421954 |
| Diluted Shares Outstanding | 29323266 | 29253763 | 29181437 | 29143354 | 29421954 |
Income Statement Trend
Ion Beam Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 72.2M | 109.3M | 158.4M | 199.3M | 151.3M |
| Short-term Investments | 416.0K | 309.0K | 12.7M | - | 1.6M |
| Accounts Receivable | 81.5M | 107.6M | 111.6M | 75.8M | 103.4M |
| Inventory | 152.8M | 130.5M | 101.0M | 74.9M | 84.5M |
| Other Current Assets | 1.0K | - | - | - | - |
| Total Current Assets | 447.7M | 452.0M | 500.5M | 427.2M | 412.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 15.3M | 13.1M | 10.2M | 10.2M | 9.2M |
| Goodwill | 37.4M | 33.6M | 28.1M | 11.4M | 12.2M |
| Intangible Assets | 14.0M | 13.2M | 7.6M | 3.8M | 4.5M |
| Long-term Investments | 46.0K | 510.0K | 42.0K | 13.0K | 600.0K |
| Other Non-Current Assets | 2.8M | 2.3M | 35.2M | 607.0K | 787.0K |
| Total Non-Current Assets | 168.4M | 145.5M | 123.4M | 118.9M | 98.5M |
| Total Assets | 616.1M | 597.5M | 623.9M | 546.1M | 511.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 79.5M | 76.6M | 65.6M | 47.7M | 41.9M |
| Short-term Debt | 17.8M | 12.6M | 9.4M | 15.1M | 20.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | 1.1M | 1.1M |
| Total Current Liabilities | 469.0M | 452.6M | 461.2M | 348.6M | 275.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 25.9M | 29.0M | 31.5M | 53.9M | 65.8M |
| Deferred Tax Liabilities | 197.0K | 286.0K | 756.0K | 197.0K | 521.0K |
| Other Non-Current Liabilities | 2.3M | 3.0M | 5.9M | 8.4M | 19.3M |
| Total Non-Current Liabilities | 36.2M | 38.7M | 46.8M | 71.6M | 93.5M |
| Total Liabilities | 505.2M | 491.3M | 507.9M | 420.2M | 369.2M |
| Equity | |||||
| Common Stock | 42.5M | 42.5M | 42.5M | 42.4M | 42.3M |
| Retained Earnings | 39.4M | 36.1M | 51.4M | 51.2M | 51.9M |
| Treasury Stock | 15.9M | 18.2M | 18.3M | 12.6M | 5.9M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 110.9M | 106.2M | 116.0M | 125.9M | 141.8M |
| Key Metrics | |||||
| Total Debt | 43.7M | 41.6M | 40.9M | 69.0M | 86.1M |
| Working Capital | -21.3M | -556.0K | 39.3M | 78.6M | 136.8M |
Balance Sheet Composition
Ion Beam Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 9.3M | -9.1M | 6.1M | 3.9M | 31.9M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -32.7M | -29.9M | -14.6M | 63.1M | 46.8M |
| Operating Cash Flow | -35.5M | -45.4M | -15.9M | 57.9M | 79.9M |
| Investing Activities | |||||
| Capital Expenditures | -4.3M | -5.3M | -3.2M | -4.2M | -2.6M |
| Acquisitions | -2.5M | -270.0K | -11.8M | 1.3M | -1.6M |
| Investment Purchases | -177.0K | 0 | 0 | -4.4M | 0 |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -7.1M | -5.3M | -15.1M | -7.4M | -4.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | -5.2M | -11.2M | - |
| Dividends Paid | -4.9M | -6.1M | -5.6M | -5.8M | -2.3M |
| Debt Issuance | - | - | - | 0 | 25.5M |
| Debt Repayment | -3.7M | -1.0M | -24.7M | -13.0M | -4.7M |
| Financing Cash Flow | -3.8M | -7.1M | -33.1M | -28.4M | 20.9M |
| Free Cash Flow | -18.0M | -32.1M | 14.4M | 82.2M | 96.4M |
| Net Change in Cash | -46.5M | -57.8M | -64.0M | 22.1M | 96.6M |
Cash Flow Trend
Ion Beam Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
33.21
Forward P/E
13.35
Price to Book
3.78
Price to Sales
0.67
PEG Ratio
13.35
Profitability Ratios
Profit Margin
2.05%
Operating Margin
6.47%
Financial Health
Current Ratio
0.94
Debt to Equity
0.56
Beta
1.22
Per Share Data
EPS (TTM)
€0.43
Book Value per Share
€3.78
Revenue per Share
€21.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IBAB | 411.9M | 33.21 | 3.78 | 0.00% | 2.05% | 0.56 |
| Sequana Medical NV | 40.6M | -0.46 | - | 100.62% | 74.94% | -1.06 |
| Argenx SE | 41.4B | 39.84 | 6.59 | 20.15% | 30.50% | 0.64 |
| Fagron NV | 1.7B | 19.15 | 3.15 | 17.24% | 9.56% | 84.34 |
Financial data is updated regularly. All figures are in the company's reporting currency.